Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase I/II Study of Talazoparib or Temozolomide in Combination With Onivyde in Children With Recurrent Solid Malignancies and Ewing Sarcoma

NCT04901702 is registered in ClinicalTrials.gov with St. Jude Children's Research Hospital as lead sponsor.

NCT NCT04901702
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04901702 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase I/II Study of Talazoparib or Temozolomide in Combination With Onivyde in Children With Recurrent Solid Malignancies and Ewing Sarcoma
Lead sponsor
St. Jude Children's Research Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 9, 2021
Completion date
December 31, 2026
Enrollment
90 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent ewing sarcoma, recurrent hepatoblastoma, recurrent malignant germ cell tumor, recurrent malignant solid neoplasm, recurrent neuroblastoma, recurrent osteosarcoma, recurrent peripheral primitive neuroectodermal tumor, recurrent rhabdoid tumor, recurrent rhabdomyosarcoma, recurrent soft tissue sarcoma, recurrent solid tumor, recurrent wilms tumor, refractory ewing sarcoma, refractory hepatoblastoma, refractory malignant germ cell tumor, refractory malignant solid neoplasm, refractory neuroblastoma, refractory osteosarcoma, refractory peripheral primitive neuroectodermal tumor, refractory rhabdoid tumor, refractory rhabdomyosarcoma, refractory soft tissue sarcoma